Clinical Trial

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, exploratory dose-escalation and dose-finding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with R/R MM and PCL.RRMM and RRpPCL
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-04.
Trial Details
NCT Number NCT06718270
Lead Sponsor Shanghai Changzheng Hospital
Collaborators: CARsgen Therapeutics Co., Ltd.
Conditions Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia
Enrollment 24 participants
Start Date 2024-12-11
Primary Completion 2027-01-03 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-12